Navigation Links
Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2013

PALO ALTO, Calif., April 24, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings of $1.02 per diluted share in the second quarter of fiscal year 2013, up 9 percent from $0.94 in the year-ago quarter.  The results for the second quarter of fiscal year 2013 included a $2.6 million restructuring charge related to the completion of the previously announced enhanced retirement program. Varian's company-wide revenues totaled $768 million for the second quarter of fiscal year 2013, up 7 percent from the year-ago quarter.  Varian ended the second quarter of fiscal year 2013 with a $2.8 billion backlog, up 4 percent from the end of the second quarter of fiscal year 2012.

"Varian's revenues and net earnings continued to grow during the second quarter in line with our expectations for the company," said Dow R. Wilson, CEO of Varian Medical Systems.  "Net orders rose in double digits for our X-Ray Products business, but fell in our Oncology business, principally because of weakness in mature U.S. and Western European markets as well as a tough quarter-over-quarter comparison in Asia and negative fluctuations in currency exchange rates, predominantly in Japan." 

The company finished the second quarter of fiscal year 2013 with $740 million in cash and cash equivalents and $238 million of debt.  During the second quarter of fiscal year 2013, cash flows from financing activities included $90 million toward the repurchase of 1.4 million shares of common stock.

Oncology Systems
Oncology Systems' second quarter revenues totaled $582 million, up 3 percent from the same period of fiscal year 2012.  Second-quarter net orders were $555 million, down 2 percent versus the comparable year-ago period, with a 9 percent decline in North America and a 4 percent gain outside North America. Markets outside North America represented 58 percent of Oncology net orders for the second quarter of fiscal year 2013.  On a constant currency basis, Oncology Systems' second quarter net orders were roughly equal to the second quarter of fiscal year 2012.  Compared to the prior-year second quarter, net orders outside North America were up 7 percent on a constant currency basis.

"While revenues and operating income grew as expected during the second quarter, net orders for the Oncology Systems business were disappointing, particularly in the U.S. where ongoing uncertainties regarding healthcare reform and reimbursement contributed to slow capital expenditures," Wilson said.  "Strong performance in emerging markets drove the orders growth outside of North America."

X-Ray Products
Second quarter revenues for the X-Ray Products business were $140 million, up 14 percent from the year-ago quarter.  X-Ray Products' second quarter net orders were $144 million, up 10 percent from the year-ago quarter.

"The X-Ray Products business delivered another solid quarter of growth in orders, revenues, and operating profits," Wilson said.  "Revenue growth in this business was helped by demand for new tube and panel products.  Tight cost control, together with higher shipment volumes, drove a healthy increase in operating income." 

The company's Other category, which includes the Security and Inspection Products business and the Varian Particle Therapy business, recorded second quarter revenues of $46 million, up $14 million from the total in the year-ago quarter.  Net orders for the Other category were $37 million for the second quarter, down $131 million from the year-ago quarter when the company booked two orders for proton therapy systems in Saudi Arabia and Russia. 

"The company remains on track for achieving its fiscal 2013 growth targets," said Wilson.  "For the third quarter of fiscal year 2013, total company revenues could increase by about 7 percent over the prior-year quarter.  Net earnings per diluted share for the third quarter should be in the range of $0.98 to $1.02.  For the fiscal year, we continue to believe that total company revenues could increase by about 8 percent over the prior fiscal year and that net earnings per diluted share for the fiscal year could be in the range of $4.09 to $4.14."

Investor Conference Call
Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2013 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at where it will be archived for a year.  To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S.  The replay can be accessed by dialing 1-877-660-6853 from inside the U.S or 1-201-612-7415 from outside the U.S. and entering confirmation code 410801.  The telephone replay will be available through 5 p.m. PT, Friday, April 26, 2013.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 6,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as our Edge™ radiosurgery system, TrueBeam™ and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms  "could," "believe,"  "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; the impact of  the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:Elisha Finney (650) 424-6803

Spencer Sias (650) 424-5782

A summary of earnings and other financial information follows.Varian Medical Systems, Inc. and Subsidiaries
 Condensed Consolidated Statements of Earnings


(Dollars and shares in millions, except per share amounts)Q2 QTR2013Q2 QTR2012Q2 YTD2013Q2 YTD2012Net orders


735.8862.81,355.01,468.9  Oncology Systems555.1564.81,032.01,049.5  X-Ray Products143.7130.4276.9240.2  Other37.0167.646.1179.2Order Backlog




768.4720.31,446.81,345.6  Oncology Systems581.8565.41,106.11,053.0  X-Ray Products140.4122.8273.3235.8  Other46.232.167.456.8Cost of revenues


448.8423.6836.1780.1Gross margin319.6296.7610.7565.5  As a percent of revenues41.6%41.2%42.2%42.0%Operating expenses  Research and development  50.947.198.090.9  Selling, general and administrative  113.0105.8219.5201.9Operating earnings 155.7143.8293.2272.7  As a percent of revenues20.3%20.0%20.3%20.3%Interest income, net0. before taxes156.3144.2294.5273.4Taxes on earnings 43.536.486.475.4Net earnings


112.8107.8208.1198.0  As a percent of revenues14.7%15.0%14.4%14.7%Net earnings per share – basic


1.040.961.911.76 Net earnings per share – diluted


1.020.941.881.73Shares used in the calculation of net earnings per share: 
Average shares outstanding - basic108.8112.4109.0112.3Average shares outstanding - diluted110.7114.5110.9114.4 Varian Medical Systems, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(In thousands)March 29,  September 28,20132012 (1)(Unaudited)AssetsCurrent assetsCash and cash equivalents




704,570Short-term investment 56,13749,709Accounts receivable, net722,979691,806Inventories502,598457,869Deferred tax assets and other304,907266,561Total current assets2,326,3542,170,515Property, plant and equipment683,593653,424Accumulated depreciation and amortization(380,850)(356,832)Property, plant and equipment, net302,743296,592Goodwill222,198222,242Other assets210,784189,377Total assets$



2,878,726Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$



180,736Accrued expenses293,594336,568Deferred revenues149,376130,883Advance payments from customers382,888380,545Product warranty51,40952,799Short-term borrowings231,873155,000Total current liabilities1,288,9991,236,531Other long-term liabilities138,963126,169Long-term debt6,2506,250Total liabilities1,434,2121,368,950Stockholders' EquityCommon stock 108,522109,407Capital in excess of par value 628,569563,875Retained earnings and accumulated other comprehensive loss  890,776836,494Total stockholders' equity1,627,8671,509,776Total liabilities and stockholders' equity$



2,878,726(1)  The condensed consolidated balance sheet as of September 28, 2012 was derived from audited financial statements as of that date. 

SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
5. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
8. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
9. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
11. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
Post Your Comments:
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... ... On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach ... works! , Countless deodorants flood the aisles that contain harmful chemicals that should ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... 2017 North American CAREGiverSM of the Year for her extraordinary compassion and lifelong ... its 60,000 North American professional caregivers for the prestigious award each year – ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Goodcents Deli Fresh ... in the Lincoln, Neb. area this year. , The first new location will ... second location will open at 84th and Northern Lights Drive this fall. And the ...
(Date:4/27/2017)... ... 27, 2017 , ... Are you investing in the safety of your friends ... during the summer. While most of us assume this type of accident will never ... few people are taking the time to learn how to respond effectively or prevent ...
(Date:4/26/2017)... MN (PRWEB) , ... April 26, 2017 , ... ... that improve supply management in hospitals, today announced it has completed a round ... Black Granite Capital LLC and its partners. Black Granite Capital is a growth ...
Breaking Medicine News(10 mins):